Clinical Guides
Ectopic Pregnancy: Diagnosis, Stabilisation and Definitive Care
A practical guide to recognising rupture, managing pregnancy of unknown location, and selecting safe expectant, medical or surgical care with reliable follow-up.
MedNext Academy | 13 min read
Ectopic Pregnancy: Diagnosis, Stabilisation and Definitive Care
A practical guide to recognising rupture, managing pregnancy of unknown location, and selecting safe expectant, medical or surgical care with reliable follow-up.
Summary
An ectopic pregnancy is implantation outside the endometrial cavity, most often in a fallopian tube. It can rupture and cause catastrophic intraperitoneal haemorrhage before a large volume of vaginal bleeding is visible. Any reproductive-age patient with abdominal or pelvic pain, vaginal bleeding, syncope or unexplained shock should have pregnancy status considered, even if amenorrhoea is absent or contraception was used. Immediate priorities in suspected rupture are recognition, senior obstetric and anaesthetic help, resuscitation, blood sampling and cross-match, and transfer to an operating theatre capable of controlling haemorrhage; imaging must not delay life-saving surgery in an unstable patient. A stable patient requires transvaginal ultrasound interpreted with symptoms, gestation and quantitative serum hCG. A positive pregnancy test with no intrauterine or extrauterine pregnancy seen is a pregnancy of unknown location, not a diagnosis of miscarriage or ectopic pregnancy. Until location or resolution is established, ectopic pregnancy remains possible. Serial hCG helps assess trophoblastic change but cannot locate a pregnancy by itself. Confirmed unruptured tubal ectopic pregnancy may be managed expectantly, with methotrexate or surgically according to stability, pain, ultrasound findings, hCG, contraindications, patient preference, access and ability to complete follow-up. Every non-surgical pathway requires documented surveillance until resolution and 24-hour return instructions because rupture can occur despite falling hCG. RhD testing and anti-D decisions must follow current Indian or institutional policy; international thresholds changed recently and should not be copied uncritically.
How Common Is It?
Ectopic pregnancy is uncommon relative to intrauterine pregnancy but common enough to be a core cause of early-pregnancy morbidity and preventable maternal death. Published rates depend on the denominator, diagnostic access, fertility treatment use and completeness of surveillance, so a rate from a high-income early-pregnancy service should not be presented as an Indian national estimate. Tubal implantation accounts for the great majority; interstitial, cervical, ovarian, caesarean-scar and abdominal pregnancies are less frequent but can be particularly hazardous and often require specialist imaging and management. Heterotopic pregnancy means simultaneous intrauterine and extrauterine pregnancies. It is rare after spontaneous conception but becomes more relevant after assisted reproduction, so seeing an intrauterine pregnancy does not always end the search when symptoms or risk are concerning. Case recognition is affected by access. In a setting with rapid transvaginal ultrasound and serial hCG, many ectopic pregnancies are identified before rupture. Where patients travel far, present first to a pharmacy, cannot return for blood tests, or have limited ultrasound access, rupture may be the first definitive presentation. The frequency of the classic triad of amenorrhoea, pain and bleeding is too low for it to be a safe screening rule. Population burden should therefore be translated into practice as a low threshold for pregnancy testing, rapid triage of instability and a follow-up system that does not lose pregnancies of unknown location.
Risk Factors
Prior ectopic pregnancy is a strong risk factor and should prompt early localisation in a subsequent pregnancy. Tubal damage from pelvic inflammatory disease, previous salpingitis, pelvic or tubal surgery, endometriosis and some infertility histories also increases risk. Assisted reproductive technology raises the likelihood of ectopic and heterotopic implantation; transfer of an embryo does not guarantee an intrauterine location. Pregnancy with an intrauterine device in situ is uncommon because the device prevents pregnancy effectively, but if pregnancy occurs, the relative possibility of ectopic implantation warrants urgent localisation. Progestogen-only contraception and sterilisation failure are other contexts in which a positive test with pain should not be dismissed. Smoking is associated with increased risk. Caesarean history is relevant to caesarean-scar pregnancy, while prior salpingectomy does not make ectopic pregnancy impossible because interstitial or contralateral implantation can occur. Risk factors guide vigilance, not diagnosis. Many patients with ectopic pregnancy have no recognised risk factor, and absence of pelvic infection history is not reassuring enough to defer assessment. Conversely, a risk factor plus a positive test does not prove ectopic pregnancy; premature methotrexate can terminate a viable intrauterine pregnancy or expose a patient unnecessarily. History must also assess likelihood of safe follow-up: travel distance, telephone access, cost, caregiving responsibilities and willingness to return are clinical determinants of whether expectant or medical management is safe. Anaemia, anticoagulation, transfusion constraints and significant comorbidity increase the consequences of bleeding and may lower the threshold for definitive treatment.
Diagnosis
History
Ask the last menstrual period, cycle certainty, pregnancy test, pain onset and laterality, vaginal bleeding, shoulder-tip pain, rectal pressure, dizziness and syncope. Record fertility treatment, prior ectopic pregnancy, infection or surgery, contraception, desired pregnancy and blood group history. A patient may not report amenorrhoea, and pain may be diffuse. ### Examination Begin with appearance, mental status, pulse, blood pressure, respiratory rate, oxygen saturation, perfusion and abdominal tenderness or guarding. Hypotension is late; tachycardia, pallor, collapse or disproportionate pain may indicate bleeding. Perform a gentle pelvic examination only when it will change care and will not delay resuscitation or ultrasound; cervical excitation or adnexal tenderness is neither sufficiently sensitive nor specific alone. ### Investigations Perform a sensitive urine or serum pregnancy test. Obtain full blood count, group and RhD type, cross-match, renal and liver tests, and coagulation studies according to severity and treatment options. Transvaginal ultrasound is the main localisation test; describe definite findings rather than relying on a single discriminatory hCG value. In pregnancy of unknown location, symptoms take priority. Current guidelines advises two hCG measurements as close as possible to 48 hours apart, not earlier. A rise greater than 63% suggests a developing intrauterine pregnancy but does not exclude ectopic; a fall greater than 50% suggests a failing pregnancy; intermediate change requires review within 24 hours. Do not use progesterone as an adjunct to determine location. Repeat ultrasound and senior review complete the pathway.
Differential Diagnosis
Threatened or early intrauterine pregnancy may cause light bleeding and cramping, while miscarriage may cause increasing bleeding, pain, cervical change or passage of tissue. Neither can be diagnosed safely from bleeding alone, and decidual tissue does not prove that an intrauterine gestation has passed. Pregnancy of unknown location is a temporary classification that can evolve into a viable intrauterine pregnancy, failing pregnancy, resolved pregnancy of unknown location or ectopic pregnancy. Corpus luteum cysts can cause unilateral pain and appear as adnexal structures; ovarian torsion produces abrupt severe pain, often with vomiting, and needs urgent surgery independent of pregnancy location. Haemorrhagic ovarian cyst, pelvic inflammatory disease, appendicitis, urinary infection, renal colic and gastroenteritis may mimic ectopic pregnancy. In upper abdominal or shoulder discomfort, consider intraperitoneal blood but also biliary, pulmonary and cardiac causes. Cervical, interstitial, caesarean-scar and abdominal ectopic pregnancies require careful ultrasound localisation because management and haemorrhage risk differ from a straightforward tubal ectopic. Heterotopic pregnancy must be considered after assisted reproduction or when an apparent intrauterine pregnancy does not explain peritoneal signs or an adnexal mass. Gestational trophoblastic disease can produce abnormal bleeding and unusual hCG patterns, but hCG magnitude alone is not diagnostic. In shock, the practical differential includes ruptured ectopic pregnancy, ruptured ovarian cyst, sepsis, trauma and non-gynaecological intra-abdominal haemorrhage. Stabilisation and haemorrhage control take precedence over perfect diagnostic certainty.
Management
For suspected rupture or haemodynamic compromise, activate the obstetric emergency pathway, give oxygen when indicated, establish large-bore intravenous access, send urgent bloods and cross-match, begin balanced resuscitation, arrange blood products and involve an experienced surgeon and anaesthetist. Do not allow ultrasound or hCG results to delay operative control of bleeding. A stable confirmed tubal ectopic requires shared selection among expectant, medical and surgical care. Current guidelines offers expectant management when the patient is stable and pain-free, the mass is under 35 mm without visible heartbeat, hCG is 1,000 IU/L or less and follow-up is reliable; it may be considered between 1,000 and 1,500 IU/L under the same conditions. These are evidence-based example thresholds, not a substitute for the current institutional protocol. Methotrexate is appropriate only after a definitive ectopic diagnosis and exclusion of a viable intrauterine pregnancy, with acceptable clinical, ultrasound, laboratory and follow-up criteria. Surgery is first-line for instability, suspected rupture, significant pain, fetal cardiac activity, mass at least 35 mm, hCG at least 5,000 IU/L, a contraindication to methotrexate or inability to return. Laparoscopy is preferred where the patient and expertise allow; laparotomy may be necessary in shock or when laparoscopy cannot safely control haemorrhage. Give analgesia, compassionate pregnancy-loss support, written emergency instructions and a named follow-up route regardless of the chosen strategy.
Prescribing Information
Methotrexate is a folate antagonist and should be prescribed for ectopic pregnancy only by an authorised clinician within a protocol that assures diagnostic certainty, dose calculation, monitoring and emergency access. Before treatment, confirm haemodynamic stability, absence of rupture, no viable intrauterine pregnancy, acceptable full blood count, renal and liver function, and no clinically important contraindication. Contraindications or strong reasons to choose another approach include breastfeeding, immunodeficiency, significant hepatic, renal or haematological disease, active pulmonary disease or peptic ulcer, blood dyscrasia, inability to comply with follow-up, and interacting or folate-containing treatment that cannot be managed. Visible embryonic cardiac activity, high initial hCG, a larger mass and significant pain reduce success and often favour surgery. A common single-dose pathway uses body-surface-area dosing with hCG measured on days 4 and 7; inadequate decline triggers senior reassessment for another dose or surgery, and thereafter hCG is checked weekly until negative. Exact dosing and rescue rules must follow the local protocol. Counsel that pain may occur but severe, increasing or systemic symptoms require immediate reassessment; falling hCG does not eliminate rupture risk. Avoid conception for the protocol-defined interval after methotrexate, and provide precise advice about folic acid, alcohol, NSAIDs, sun exposure, medicines and breastfeeding based on the approved regimen. Analgesia, antiemetics and perioperative antibiotics should follow pregnancy, allergy and surgical guidance. Anti-D is a separate RhD prophylaxis decision, not treatment for ectopic pregnancy itself.
When to Refer
Every suspected ectopic pregnancy needs access to a clinician and facility capable of definitive localisation, serial follow-up and emergency treatment. Refer immediately with resuscitation underway if there is syncope, haemodynamic compromise, peritoneal irritation, severe or escalating pain, shoulder-tip pain with circulatory symptoms, a substantial haemoglobin fall, significant free fluid or another concern for rupture. A positive pregnancy test with pain or bleeding and no confirmed intrauterine pregnancy requires urgent early-pregnancy or gynaecology assessment; the exact timing depends on symptoms, not a solitary hCG result. A pregnancy of unknown location with worsening symptoms returns immediately regardless of previous reassuring blood trends. Current guidelines recommends review within 24 hours when 48-hour hCG falls by less than 50% or rises by less than 63%. Refer to a specialist centre for suspected interstitial, cervical, caesarean-scar, ovarian or abdominal pregnancy, heterotopic pregnancy, complex fertility treatment, or anticipated haemorrhage requiring advanced surgery or interventional radiology. If local services cannot provide transvaginal ultrasound, methotrexate monitoring, laparoscopy, blood or round-the-clock theatre, arrange transfer early rather than attempting a fragile outpatient plan. Communicate stability, access, blood group, haemoglobin, hCG trend, scan findings, treatment and consent discussion directly to the receiving team. A patient selected for outpatient care must have reliable transport, a working contact method, written danger signs and a facility that will accept an unscheduled return at any hour.
Red Flags
Collapse, syncope, confusion, marked weakness, pallor, cool peripheries, tachycardia, hypotension or oliguria suggest significant haemorrhage and require immediate action. Blood pressure can remain normal until compensation fails, so a normal reading does not override concerning symptoms or examination. Severe or increasing abdominal or pelvic pain, guarding, rebound, abdominal distension, shoulder-tip pain, rectal pressure, breathlessness or substantial free fluid raises concern for rupture. Vaginal bleeding may be slight despite major intraperitoneal blood loss. During expectant or methotrexate management, new dizziness, fainting, worsening pain, heavy bleeding, fever or feeling acutely unwell demands emergency reassessment; do not reassure solely because hCG is falling. Failure to attend scheduled hCG measurements is itself a safety failure that needs active contact and reconsideration of the management strategy, not simple discharge from follow-up. Red flags for diagnostic error include giving methotrexate when an intrauterine pregnancy has not been adequately excluded, labelling a pregnancy of unknown location as complete miscarriage without resolution, or assuming that an intrauterine gestation excludes heterotopic pregnancy after assisted reproduction. Haemoglobin can initially underestimate acute blood loss. Analgesic response does not prove stability. Any mismatch among symptoms, vital signs, ultrasound and laboratory trend should trigger senior review. Patients and families should be told explicitly that rupture can occur before the next planned test and should know the fastest route to emergency care.
Indian Clinical Context
National Health Mission training places ectopic pregnancy within early-pregnancy bleeding and comprehensive emergency obstetric care, emphasising rapid recognition of shock and management at an appropriately capable facility. In practice, capability varies widely. A primary or first-referral unit may identify pregnancy and shock but lack 24-hour transvaginal ultrasound, quantitative hCG, laparoscopy, anaesthesia or blood components. The correct response is stabilisation, early communication and escorted transfer, not waiting for every diagnostic test. Where follow-up requires repeated long-distance travel or out-of-pocket testing, expectant or methotrexate care may be medically unsuitable even if laboratory thresholds appear favourable. Ask about phone access, transport, family responsibilities and the patient's ability to return; solve barriers where possible, but choose definitive care when follow-up cannot be made safe. Maintain privacy and obtain the patient's consent before involving family. Do not confuse ectopic management with medical abortion: mifepristone and misoprostol do not treat an ectopic pregnancy. RhD-negative care is particularly vulnerable to copied protocols. current guidelines changed its anti-D recommendations in June 2026, while Indian institutional policies may use different gestational and procedural thresholds. Check the current local obstetric and blood-bank protocol, document RhD status and the decision, and avoid importing a foreign rule without governance. Record treatment, histopathology when tissue is removed, serial hCG plan, contraception or conception advice, and the route for early localisation in the next pregnancy. Audit delays, ruptures after missed follow-up and transfer failures as system events.
NMC Competency Mapping
The ectopic-pregnancy learning outcome spans early-pregnancy assessment, emergency resuscitation, ultrasound interpretation, rational therapeutics, operative decision-making, communication and referral. The learner should recognise that pain or bleeding in a reproductive-age patient requires pregnancy testing and should identify shock before hypotension appears. Under supervision, the learner should take an obstetric and gynaecological history, assess vital signs and perfusion, perform an appropriate abdominal and pelvic examination, request full blood count, group and cross-match, quantitative hCG and transvaginal ultrasound, and interpret them without using a discriminatory threshold as proof of location. The learner should define pregnancy of unknown location and construct a safe serial hCG and repeat-scan plan. Management competence includes explaining expectant, methotrexate and surgical pathways; identifying contraindications and failure criteria; initiating resuscitation; arranging blood and theatre; and performing a structured referral handover. Pharmacology integration covers methotrexate mechanism, pre-treatment tests, adverse effects, interactions, follow-up and reproductive counselling. Professional competencies include informed consent, confidentiality, non-judgemental pregnancy-loss care, respect for patient preferences and documentation of uncertainty. Systems learning should address rural transfer, follow-up reliability, blood availability and local RhD policy. NMC CBME mapping must use the current college ledger rather than an invented code: a learner may know the principles before being entrusted to prescribe methotrexate or perform surgery. Simulation should assess deterioration, team leadership and escalation as well as recall.
Key Exam Pearls for NEET PG
The classic triad of amenorrhoea, pain and vaginal bleeding is not reliably present. Always consider pregnancy in a reproductive-age patient with abdominal pain, bleeding, syncope or unexplained shock. Tubal pregnancy is most common, but interstitial, cervical, ovarian, caesarean-scar, abdominal and heterotopic pregnancies matter. A pregnancy of unknown location means a positive pregnancy test with neither intrauterine nor extrauterine pregnancy identified on ultrasound; it is a temporary state and ectopic pregnancy remains possible until location or resolution. Serum hCG indicates trophoblastic change, not anatomical location. Current guidelines uses two samples about 48 hours apart: a rise over 63% suggests a developing intrauterine pregnancy but cannot exclude ectopic; a fall over 50% suggests a failing pregnancy; an intermediate trend requires prompt review. Do not use serum progesterone to locate the pregnancy. Instability, rupture, significant pain, fetal cardiac activity, a mass at least 35 mm, hCG at least 5,000 IU/L or unreliable follow-up favours surgery in the current pathway. Methotrexate requires diagnostic certainty, stability, acceptable blood count, renal and liver function and reliable surveillance; check hCG on days 4 and 7 in a common single-dose protocol, then weekly until negative. Rupture remains possible while hCG falls. Laparoscopic salpingectomy is usual when the other tube is healthy; salpingotomy may preserve a compromised fertility pathway but needs postoperative hCG because trophoblast may persist. Rh prophylaxis varies by current jurisdiction and procedure—use the local protocol.
Frequently Asked Questions
Can ectopic pregnancy be excluded when the first transvaginal ultrasound shows no adnexal mass?
No. A positive test with no identified intrauterine or extrauterine pregnancy is a pregnancy of unknown location. The patient remains at risk until repeat ultrasound, serial hCG and clinical follow-up establish location or complete resolution. Symptoms override a previously non-diagnostic scan, and worsening pain, dizziness or collapse requires immediate reassessment.
Does a normally rising serum hCG concentration prove that the pregnancy is intrauterine?
No. hCG describes trophoblastic proliferation and cannot determine anatomical location. A rise greater than the pathway threshold makes a developing intrauterine pregnancy more likely, but ectopic pregnancy is still possible. Location requires appropriate ultrasound and follow-up; a single discriminatory value should not be used to give methotrexate or to end surveillance.
Who is not a safe candidate for methotrexate treatment of ectopic pregnancy?
Patients with instability, suspected rupture, significant pain, inability to return, an unexcluded viable intrauterine pregnancy, important hepatic, renal or haematological disease, breastfeeding or other protocol contraindications should not receive routine methotrexate. Visible cardiac activity, a larger mass and high hCG also reduce success and commonly favour surgery. Exact criteria belong to the current institutional protocol.
What follow-up and future-pregnancy advice is needed after an ectopic pregnancy?
Confirm biochemical resolution after expectant care, methotrexate and any surgery that can leave trophoblast, with the schedule determined by the treatment protocol. Provide emergency return instructions, emotional support and individualised contraception or conception advice. After methotrexate, use the protocol-defined delay before conception. In the next pregnancy, arrange early assessment and ultrasound to confirm location.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic